We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $20B
1-Year Est. Return 154.41%
This Fund
S&P 500
This Quarter Est. Return
+25.43%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$16.7B
AUM Growth
+$1.38B
Cap. Flow
-$374M
Cap. Flow %
-2.25%
Top 10 Hldgs %
86.98%
Holding
128
New
13
Increased
17
Reduced
8
Closed
15

Top Buys

Rank Stock Value
1
SWTX
SpringWorks Therapeutics
SWTX
+$37.7M
2
PRME icon
Prime Medicine
PRME
+$18.6M
3
DNLI icon
Denali Therapeutics
DNLI
+$14.9M
4
REPL icon
Replimune Group
REPL
+$14.2M
5
SPRY icon
ARS Pharmaceuticals
SPRY
+$13M

Top Sells

Rank Stock Value
1
GBT
Global Blood Therapeutics, Inc.
GBT
+$254M
2
CCXI
ChemoCentryx, Inc.
CCXI
+$92.6M
3
TVTX icon
Travere Therapeutics
TVTX
+$44M
4
FMTX
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
+$37.6M
5
RLMD icon
Relmada Therapeutics
RLMD
+$18.3M

Sector Composition

Rank Sector Weight
1 Healthcare 99.83%
2 Miscellaneous 0.16%
3 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ZYME icon
51
Zymeworks
ZYME
$1.86B
$13.4M 0.08%
1,708,472
– –
WHWK
52
Whitehawk Therapeutics
WHWK
$233M
$12.7M 0.08%
989,928
– –
CABA icon
53
Cabaletta Bio
CABA
$441M
$12.4M 0.07%
1,344,000
+681,937
+103% +$2.48M
VSTM icon
54
Verastem
VSTM
$665M
$10.9M 0.07%
2,249,075
– –
ALT icon
55
Altimmune
ALT
$628M
$10.8M 0.06%
653,562
-1,116,119
-63% -$12.5M
STOK icon
56
Stoke Therapeutics
STOK
$1.82B
$10.2M 0.06%
1,108,913
+739,586
+200% +$7.69M
CINC
57
DELISTED
CinCor Pharma, Inc. Common Stock
CINC
$9.92M 0.06%
807,212
– –
VOR icon
58
Vor Biopharma
VOR
$1.32B
$9.75M 0.06%
73,296
– –
RNAM
59
DELISTED
Avidity Biosciences
RNAM
$9.65M 0.06%
+434,782
New +$6.48M
PACB icon
60
Pacific Biosciences
PACB
$417M
$9.23M 0.06%
1,127,782
– –
PNT
61
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$8.52M 0.05%
1,169,103
– –
RETA
62
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$8.51M 0.05%
223,976
– –
SMMT icon
63
Summit Therapeutics
SMMT
$13.9B
$8.5M 0.05%
+2,000,000
New +$3.64M
VERU icon
64
Veru
VERU
$39.9M
$8.5M 0.05%
160,958
– –
AFMD
65
DELISTED
Affimed
AFMD
$8.18M 0.05%
659,683
– –
CMPX icon
66
Compass Therapeutics
CMPX
$333M
$7.83M 0.05%
+1,557,630
New +$6.21M
DSGN icon
67
Design Therapeutics
DSGN
$765M
$7.1M 0.04%
692,131
-744,505
-52% -$10.1M
BHVN icon
68
Biohaven
BHVN
$1.86B
$6.61M 0.04%
+476,190
New +$6.72M
VERA icon
69
Vera Therapeutics
VERA
$2.43B
$6.45M 0.04%
333,333
– –
ALEC icon
70
Alector
ALEC
$228M
$6.29M 0.04%
681,991
+442,763
+185% +$3.86M
MGNX icon
71
MacroGenics
MGNX
$257M
$5.99M 0.04%
892,579
– –
LONA
72
LeonaBio Inc
LONA
$68.2M
$5.96M 0.04%
187,984
+83,901
+81% +$2.64M
IPSC icon
73
Century Therapeutics
IPSC
$359M
$5.9M 0.04%
1,149,340
+778,753
+210% +$7.35M
ROIV icon
74
Roivant Sciences
ROIV
$28.5B
$5.73M 0.03%
+716,653
New +$3.99M
TNGX icon
75
Tango Therapeutics
TNGX
$4.03B
$5.44M 0.03%
750,000
– –
1 2
3
4 5

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Baker Bros. Advisors's Q4 2022 Portfolio in Review

As of Q4 2022, Baker Bros. Advisors held 128 positions worth $16.7B, up 9.1% from $15.3B the previous quarter. Its ten largest holdings account for 87% of the portfolio.

Baker Bros. Advisors's Q4 2022 filing shows 13 new, 17 increased, 8 reduced and 15 closed positions. Its largest new stake was SpringWorks Therapeutics: 1,528,538 shares worth $39.8M. The largest sale was Global Blood Therapeutics, Inc., an estimated $254M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Miscellaneous and Financials.

  • Baker Bros. Advisors's largest Q4 2022 buy was SpringWorks Therapeutics: 1,528,538 shares worth $39.8M.
  • Baker Bros. Advisors added most to Denali Therapeutics in Q4 2022, an estimated $14.9M increase.
  • Baker Bros. Advisors's biggest Q4 2022 reduction was Travere Therapeutics, cutting an estimated $44M.
  • Baker Bros. Advisors fully exited Global Blood Therapeutics, Inc. in Q4 2022, selling an estimated $254M.
  • Baker Bros. Advisors's ten largest holdings make up 87% of its $16.7B portfolio in Q4 2022.
  • Baker Bros. Advisors opened 13 new positions and closed 15 in Q4 2022.
  • Baker Bros. Advisors's portfolio value rose 9.1% quarter-over-quarter to $16.7B.

Based on Baker Bros. Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.